Gibbs John F, Schlieman Michael, Singh Paramvir, Saxena Rakhee, Martinick Maisie, Hutson Alan D, Corasanti James
Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, NY 14263, USA.
HPB Surg. 2009;2009:805971. doi: 10.1155/2009/805971. Epub 2009 Nov 30.
We have previously demonstrated that uPA is overexpressed in pancreatic tumors. In an attempt to diagnose these tumors earlier, we sought to determine whether uPA could be identified in endoscopic retrograde cholangiopancreatography obtained brushings in patients with malignant pancreatic and biliary strictures. Secondarily, uPA was measured in the serum of this patient population. uPA overexpression was identified in the cytologic tissue in 8 of 11 patients (72.7%). Serum analysis demonstrated a 2-fold higher concentration of uPA in the pancreaticobiliary cancer patients (1.27 versus 0.56 ng/mL; P = .0182). Also, uPA overexpression correlated with serum levels (P < .0001). This study confirms that uPA can be detected in the ERCP cytologically obtained tissue and is frequently present in a higher concentration in the serum of pancreaticobiliary cancer patients. A larger sample size will be required to address its value as a sensitive marker for the diagnosis of pancreatic or biliary cancers.
我们之前已经证明,尿激酶型纤溶酶原激活剂(uPA)在胰腺肿瘤中过度表达。为了更早地诊断这些肿瘤,我们试图确定在患有恶性胰腺和胆管狭窄的患者的内镜逆行胰胆管造影获得的刷片中是否可以检测到uPA。其次,对该患者群体的血清进行了uPA检测。11例患者中有8例(72.7%)在细胞学组织中检测到uPA过度表达。血清分析显示,胰胆管癌患者的uPA浓度高出2倍(1.27对0.56 ng/mL;P = 0.0182)。此外,uPA过度表达与血清水平相关(P < 0.0001)。本研究证实,uPA可在内镜逆行胰胆管造影细胞学获得的组织中检测到,并且在胰胆管癌患者的血清中经常以较高浓度存在。需要更大的样本量来评估其作为胰腺癌或胆管癌诊断敏感标志物的价值。